Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
FRANKLIN LAKES, N.J., July 30 /PRNewswire-FirstCall/ -- A new analysis finds that women in New Jersey who take the breast
cancer drug tamoxifen in conjunction with certain popular antidepressants may be at a higher risk for a breast
In May, Medco Health Solutions, ...
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA
(Alternext: ALIPS) today reported that the St. Gallen International Consensus
Panel on the Primary Therapy of Early Breast
Cancer indicated for the first
time that the Genomic Grade could be considered as an adjunct to the
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast
cancer met its primary and ...
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced the
inclusion of its breast
cancer recurrence test MammaPrint in St. Gallen's
2009 International Expert Consensus on the primary therapy of early breast
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
- 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial -
BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients w...
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ --
- Data Highlighted in Plenary Session of 2009 American Society of
Clinical Oncology Annual Meeting
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and its fully owned
subsidiary, BiPar Sciences, today announced resu...
New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
- Several SSRIs more than double risk of cancer recurrence in tamoxifen treated patients
- Nearly 30 percent of tamoxifen users take drugs that reduce its effectiveness against breast
ORLANDO, Fla., May 30 /PRNewswire-FirstCall/ -- An important new study finds that certain popula...
New Research Shows Antidepressants May Thwart Breast Cancer Treatment
Popular antidepressants taken with tamoxifen can increase the risk of breast
PHILADELPHIA, May 30 /PRNewswire-USNewswire/ -- A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast
cancer recurrence in women taking both ...
Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
Abstract # 25670
ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast
cancer research conducted at the Barbara Ann Karmanos Cancer Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking fi...
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...
Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
- Largest Genomic Study Comparing Gene Expression in Female and Male Patients Presented at ASCO Annual Meeting -
ORLANDO, Fla., May 29 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced results from a study which summarized the gene signatures identified by the O...
Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
ATLANTA, May 8 /PRNewswire/ -- On May 9th, the Hooters of Orange Park is hosting a car wash to raise money for breast
cancer research. The car wash begins at 10 AM at the Hooters of Orange Park located at 1740 Wells Road. The restaurant can be reached at (904) 215-5858.
All donations from t...
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
-Preliminary Data from This Trial to be Presented at ASCO-
-First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment-
TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment...
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
Abstract # 2905
DENVER, April 20 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 100th Annual Meeting 2009 that represents significant research advancements in the treatment ...
ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics
(Alternext: ALEHT) today reported the publication in Lancet Oncology of a
study conducted by Institut Gustave Roussy, which describes the
identification of a deregulated cell function in breast
cancer through the
analysis of altern...
SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists
CHICAGO, March 2 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) and the American College of Obstetricians and Gynecologists (ACOG) have jointly developed a breast
disease fellowship training program for gynecologic oncologists. Supported by a grant of $75,000 fr...
BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
MOUNTAIN VIEW, California, February 23 /PRNewswire/ -- BN
ImmunoTherapeutics, Inc. today provided updated data from its clinical
studies with its breast
cancer vaccine, MVA-BN(R)-HER2, in development as
therapy of metastatic breast
cancer patients whose tumours over-express HER2.
The study met...
Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
- Adding Zometa to post-surgery hormone therapy reduced risk of breast
cancer return or death by 36% more than hormone therapy alone
- First Phase III data to substantiate anticancer effect of Zometa
- Zometa is the most widely prescribed drug for prevention of bone complications due to ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study show
that patients with metastatic breast
cancer who were treated previously with
an anthracycline in the adjuvant setting experienced a significant improvement
in time to disease progression (TTP) and overall response rates after
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company
that discovers, develops and commercializes new molecular diagnostic tests in
oncology, reported today findings from three studies using the company's
cancer assay to predict risk of disease recurrence in
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ --
Dr. Michael Knauer from the Netherlands Cancer Institute today announced data
uncovering a substantial group of traditionally miscategorized low risk HER2+
patients. Agendia's highly accurate breast
cancer tumor recurrence tes...
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early
clinical studies show that RAD001(R) (everolimus) may overcome resistance to
Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast
cancer. These results support the initiation of a Phase III clinical trial
New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
PHILADELPHIA and SAN ANTONIO, Texas, Dec. 12 /PRNewswire-USNewswire/ -- A
groundbreaking study developed by Breastcancer.org reports that American girls
are significantly affected by the steady stream of information and messaging
cancer. This study surveyed over 2,400 girls ages 8-1...
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
HUNTINGTON BEACH, California and AMSTERDAM, December 12 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced
MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in
Dr. Laura van 't Veer, from the Netherlands Cancer Inst...
Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
- Femara showed reduced risk of death by 13% (P=0.08), despite inclusion of patients crossing over from tamoxifen to Femara therapy
- In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19%
- Long-term follow-up fro...
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at
the CTRC-AACR San Antonio Breast
Cancer Symposium (SABCS) show that Herceptin
(trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue
to offer new and better treatment options for breast
cancer patients al...
Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced that
leading Agendia and the Netherlands Cancer Institute researchers will present
data from multiple studies at the 2008 San Antonio Breast
New Breast Imaging Technology Targets Hard-to-Detect Cancers
CHICAGO, Dec. 3 /PRNewswire-USNewswire/ -- Breast-specific gamma imaging
(BSGI) is effective in the detection of cancers not found on mammograms or by
clinical exam, according to a study presented today at the annual meeting of
the Radiological Society of North America (RSNA).
"BSGI can id...
New Mammography Technology Effective in Detecting Breast Cancer
CHICAGO, Dec. 2 /PRNewswire-USNewswire/ -- A study has found that positron emission mammography (PEM), a new technique for imaging the breast, is not affected by either breast
density or a woman's hormonal status, two factors that limit the effectiveness of standard mammography and ...
Siemens Introduces New Standard of Care for Breast Ultrasound
Increased information density, automation and intelligent clinical applications take workflow efficiency in ultrasound to an all new level
CHICAGO, Ill., Nov. 26 /PRNewswire-FirstCall/ -- Siemens Healthcare ( www.siemens.com/healthcare ) highlights the ACUSON S2000(TM) Automated Brea...
Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
MARSEILLE, France, November 24 /PRNewswire-FirstCall/ -- IPSOGEN SA
(Marseille, France and New Haven, CT, USA), a cancer profiler that markets
molecular diagnostic assays for leukemia and breast
cancer announced today
the European launch of MapQuant Dx(TM) HER2 test. Developped on the MapQuant
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) announced the company will present results from the Phase 1B
clinical trial of their lead drug candidate for advanced metastatic breast
cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...
Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
India Chosen as First Commercial Market to Demonstrate Test's Potential for Rapid Uptake
OSLO and FOSTER CITY, California, November 10 /PRNewswire-FirstCall/ --
DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today
announced the launch of BCtect(TM...
Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) announced today that its drug candidate for metastatic
breast cancer, BZL101, will advance to Phase 2 clinical testing after the
successful completion of a second Phase 1 clinical trial.
The Phase 1B clinical...
NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Sanarus' Visica 2(TM) Treatment System Selected as Exclusive Cryoablation Treatment Technology
PLEASANTON, Calif., Oct. 28 /PRNewswire/ -- The American College of
Surgeons Oncology Group (ACOSOG) which just initiated a National Cancer
Institute (NCI) funded clinical tri...
Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women
SAN FRANCISCO, Oct. 15 /PRNewswire-USNewswire/ -- In a national study
presented earlier today at the 2008 American College of Surgeons (ACS)
Clinical Congress, a researcher reported that "women under 40 years of age
diagnosed with Stage I breast
cancer are 44 percent more likely to die than
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen of Bavituximab in Combination With Carboplatin and Paclitaxel -
TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical
company developing ...
Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial
- TARGIT Procedure May Eliminate 6 Weeks of Radiation Therapy -
Event: Watch Single-Dose Radiation Treatment over the Internet Wednesday,
October 22, 2008, 3 - 4 p.m. by visiting http://www.sentara.com/explorehealth
HAMPTON, Va., Oct. 6 /PRNewswire/ - Questions raced through Vela Cro...
Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center
Advances in diagnostics and genetic testing give women answers about their risks
DAYTON, Ohio, Oct. 1 /PRNewswire/ -- According to the U.S. Cancer
Statistics Working Group (2007), an estimated 182,460 new cases of breast
cancer will be diagnosed in American women...
New Computer-Based Tools Will Help Make Best Use of Genetic Breast Cancer Tests
ROCKVILLE, Md., Sept. 22 /PRNewswire-USNewswire/ -- A new federal
project, funded by the Agency for Healthcare Research and Quality, will
lead efforts to develop, implement and evaluate four computer-based
decision-support tools that will help clinicians and patients better use
genetic tests to...